ClinicalTrials.gg
Active, not recruitingNCT07221890Updated May 14, 2026

A Trial of Academic Detailing to Promote Prescribing of Biosimilars

An interventional study of Offered an academic detailing session and Standard-of-care outreach from the insurance plan in Autoimmune Diseases, Rheumatoid Arthritis (RA) and Inflammatory Bowel Disease (IBD), sponsored by Brigham and Women's Hospital. Active, not recruiting at 2 sites in United States. Per ClinicalTrials.gov, last updated 2026-05-14.

Primary conditionArthritis, RheumatoidRegistry: Autoimmune DiseasesReclassifiedWhy we changed it
Registry
Autoimmune Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Arthritis, Rheumatoid
Why
  1. The study's listed conditions name Arthritis, Rheumatoid, a narrower term within Autoimmune Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,325
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies in Arthritis, Rheumatoid by Brigham and Women's Hospital — 1 open to participants now, 4 under way, none of them phase 3. Arthritis, Rheumatoid · Brigham and Women's Hospital.

Planned enrollment
2nd of 18
1,325 · median 112
Started
2025
the only one that year
No phase
10 of 28
none open now
Registered
27th of 28
by date

Among the 28 studies in Arthritis, Rheumatoid by Brigham and Women's Hospital, this one is the 2nd largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2025, is one of 10 with no phase, and was the 27th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 28 studies in Arthritis, Rheumatoid by Brigham and Women's Hospital is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Arthritis, Rheumatoid by Brigham and Women's Hospital, or all of them as a file.
02

Study summary

The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are:

  1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab?
  2. Do in-person or virtual visits work better?

Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version.

Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.

Read the detailed description

This is a parallel, cluster randomized controlled trial in which medical practices with clinicians who prescribed adalimumab (Humira) to patients in a Humana Medicare Prescription Drug Plan (PDP) will be randomized to have eligible clinicians within the practice invited to participate in the educational module about biosimilars (the intervention group). Practices with eligible physicians that are not offered the educational module will serve as the comparison group (the control group). The study will include practices in all 50 US states and Washington, DC, and practices will be stratified into approximately 50 geographic regions. Regions containing about half of the eligible clinicians will have the module offered to the intervention group in-person and the other half of regions will have the module offered virtually. Practices will be randomized 2:1 to be offered detailing (intervention) vs. not be offered detailing (control). Outcomes, including the use and cost of biologics and biosimilars, will be measured from routinely-collected prescribing data using the Humana Research Database.

03

Conditions studied

  • Autoimmune Diseases
  • Rheumatoid Arthritis (RA)
  • Inflammatory Bowel Disease (IBD)
  • Psoriasis (PsO)

Keywords

  • biosimilar
  • biologic
  • academic detailing
  • clinician education
  • prescribing
  • Medicare Part D
04

In context

Arthritis, Rheumatoid Reclassified

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

This study's planned enrollment of 1,325 is above the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.

Browse Arthritis, Rheumatoid studies →

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.

Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.

Compared within Arthritis, Rheumatoid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autoimmune Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Wrote 7 or more adalimumab prescriptions that were filled by patients enrolled in research-eligible Humana Medicare Part D plans in the calendar year 2025

Exclusion criteria

Exclusion Criteria:

  • Retired
  • Not able to identify active clinical practice in the US (50 states plus Washington DC)
06

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,325 participants (estimated)

Study arms

  • Experimental
    Intervention

    Offered an academic detailing session either in-person or virtually (depending on assigned geographic region), plus standard-of-care outreach from the insurance plan.

    Other: Offered an academic detailing session · Other: Standard-of-care outreach from the insurance plan

  • Active comparator
    Control

    Not offered an academic detailing session. Standard-of-care outreach from the insurance plan.

    Other: Standard-of-care outreach from the insurance plan

Interventions

  • OtherOffered an academic detailing session

    Clinicians will be offered an academic detailing session that will be delivered by a specially trained pharmacist, nurse, or physician (i.e., detailer). These academic detailers will be provided and trained by an independent non-profit organization. After a clinician agrees to participate in an academic detailing session, the detailer will schedule a 1-on-1 meeting lasting 15-20 minutes during which the detailer will provide educational information about biosimilars tailored to their knowledge and attitudes on the topic. During the session, the clinician will be provided printed and/or digital materials, including an educational brochure and patient education materials. Clinicians will also receive access to a summary evidence document containing all of the material with citations. Clinicians will also be offered the opportunity to claim continuing medical education (CME) credits for participating.

  • OtherStandard-of-care outreach from the insurance plan

    Clinicians will receive formulary information from Humana to provide information about coverage of adalimumab (Humira) and its biosimilars.

07

What researchers measure

Primary outcomes

  1. Number of biosimilar adalimumab prescriptions per clinician

    Time frame: 12 months

  2. Number of originator adalimumab (Humira) prescriptions per clinician

    Time frame: 12 months

  3. Total spending (payer + patient) on adalimumab

    Time frame: 12 months

  4. Patient out-of-pocket spending on adalimumab

    Time frame: 12 months

Secondary outcomes

  1. Number of participants in the intervention arm who participated in an educational meeting with an academic detailer

    Time frame: 6 months

  2. Number of filled biosimilar prescriptions for other medications with biosimilar versions available, including ustekinumab, tocilizumab, and infliximab

    Time frame: 12 months

  3. Number of filled prescriptions for other brand-name disease-modifying medications that are FDA approved to treat 1 or more of the same indications as adalimumab, such as TNF-alpha inhibitors and interleukin inhibitors

    Time frame: 12 months

  4. Number of patients who fill 1 or more prescriptions for biosimilar adalimumab who subsequently switch back to originator biologic

    Time frame: 12 months

08

Study locations

2 sites
09

References and documents

Individual participant data

Plan to share: Undecided — Depends on data use agreement with Humana.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 13 months is below that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2025
First posted
Oct 28, 2025
StartActual
Nov 6, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07221890
Collaborators
Humana Healthcare Research, Inc.
Responsible party
Benjamin Rome (Assistant Professor of Medicine, Brigham and Women's Hospital) — Principal investigator
First posted
Oct 28, 2025
Start date
Nov 6, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
May 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion